Beam: base-editing development investment
Beam’s June-quarter 10-Q records $95.096M of R&D expense. A Q4 comparison follows clinical and manufacturing investment without assigning treatment-success probabilities.
Beam Therapeutics / BEAMPublic biotechR&D-spendingDate to watch
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Historical-comparison threshold; not management guidance.
Primary evidence
Reporting date unconfirmed — research candidate
Beam June 30, 2026 Form 10-Q filed with SECCompany source
Potential outcome market
Will Beam Q4 2026 GAAP R&D expense exceed $95.096 million?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.